UKUwe Kölsch

Uwe Kölsch

*This is an algorithmically generated author record based on publicly available information.

Uwe Kölsch has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Christian Meisel

    Department of Immunology, Labor Berlin Charité-Vivantes , Berlin

    2 shared publications
  • Horst von Bernuth

    Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    2 shared publications
  • Alexandra Nieters

    Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    1 shared publication
  • Alexandru Vlagea

    Department of Immunology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain

    1 shared publication
  • Ana García‐García

    Clinical Immunology and Primary Immunodeficiencies Unit, Hospital Sant Joan de Déu 9 Pediatric Allergy and Clinical Immunology Department Barcelona

    1 shared publication
  • Andreas Diefenbach

    Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin 1 Department of Microbiology, Infectious Diseases and Immunology Berlin

    1 shared publication

Latest Publications

  • Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients

    by Olga Staudacher, Tim Meyer, Bengisu Akbil, Miriam Mayer, Carolin Schmoll, Uwe Kölsch, Nadine Unterwalder, Anna Slagman, Christian Meisel, Christine Goffinet, et al.

    Neutralizing autoantibodies against type I interferons are a risk factor for multiple severe viral diseases. The timely detection of these autoantibodies remains an unmet need. We hypothesized that paradoxically low expression of type I IFN-induced CD169/SIGLEC1 expression analyzed by flow cytometry may allow rapid screening for the presence of these autoantibodies. In a prospective cohort study, we quantified monocytic CD169/SIGLEC1 expression and neutralizing autoantibodies against type I interferons in 808 patients who presented to the emergency room with signs of acute infections during the second wave of the SARS-CoV-2 pandemic in Germany in 2021. In patients, elevated CD169/SIGLEC1 (>2400 mAb/cell) demonstrated a negative predictive value of 100% for the detection of neutralizing autoantibodies against type I interferons. Low CD169/SIGLEC1 (50 mg/L exhibited a positive predictive value of 70% for neutralizing autoantibodies against type I interferons. We further compared the adjusted odds ratio for mortality in patients with these autoantibodies to that in patients without autoantibodies against type I interferons. Neutralizing autoantibodies against type I interferons were associated with a worse clinical outcome, independent of SARS-CoV-2 infection, implying their presence is a risk factor for a worse general outcome.


  • Open Access

    Clinical and immunological characterisation of patients with common variable immunodeficiency related immune thrombocytopenia

    by Nadia Somasundaram, Oliver Meyer, Carmen Scheibenbogen, Leif Gunnar Hanitsch, Anna Stittrich, Uwe Kölsch, Kirsten Wittke

    Primary Immune thrombocytopenia (ITP) is an autoimmune disease. Secondary ITP occurs in patients with underlying diseases such as common variable immunodeficiency (CVID). CVID is one of the most common symptomatic primary immunodeficiencies in adults, characterised by infectious and non-infectious symptoms. Amongst CVID patients, ITP is the most frequent autoimmune manifestation. In this single-centre study, we performed a clinical and immunological characterisation of 20 patients with CVID-related ITP and 20 ITP patients without CVID to compare severity and remission rates. We found that patients with CVID-related ITP had a higher WHO Bleeding Scale at initial diagnosis yet showed higher remission rates and required less treatment. Patients with ITP needed up to seven therapy options and were often treated with second-line drug therapy, whilst only one CVID-related ITP patient required second-line drug therapy. Therefore, we show that the course of thrombocytopenia in patients with CVID-related ITP is milder. Furthermore, we show that soluble interleukin-2 receptor (sIL-2R, CD25) was higher in CVID-related ITP compared to ITP patients and could accurately classify patient cohorts with an Area Under the Receiver Operating Characteristic of 0.92. Whilst none of the ITP patients had a history of immunodeficiency, we found immunological abnormalities in 12 out of 18 patients. Therefore, we recommend screening ITP patients for CVID and other immunodeficiencies to detect immune abnormalities early, as we found patients with reduced immunoglobulin levels as well as severe lymphocytopenia in our ITP cohort.


  • The expansion of human T-bet high CD21 low B cells is T cell dependent

    by Baerbel Keller, Valentina Strohmeier, Ina Harder, Susanne Unger, Kathryn J. Payne, Geoffroy Andrieux, Melanie Boerries, Peter Tobias Felixberger, Jonathan J. M. Landry, Alexandra Nieters, et al.

    T cell–derived IFNγ and CD40L/IL-21R signals are crucial for the differentiation of human T-bet high CD21 low B cells.


  • Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells

    by Mario Witkowski, Caroline Tizian, Marta Ferreira-Gomes, Daniela Niemeyer, Terry C. Jones, Frederik Heinrich, Stefan Frischbutter, Stefan Angermair, Thordis Hohnstein, Irene Mattiola, et al.

    SARS-CoV-2 is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Given its acute and often self-limiting course, components of the innate immune system are likely central in controlling virus replication thereby determining clinical outcome. Natural killer (NK) cells are innate lymphocytes with notable activity against a broad range of viruses, including RNA viruses1,2. NK cell function may be altered during COVID-19 despite increased representation of NK cells with an activated and ‘adaptive’ phenotype3,4. Here we show that viral load decline in COVID-19 correlates with NK cell status and that NK cells can control SARS-CoV-2 replication by recognizing infected target cells. In severe COVID-19, NK cells show remarkable defects in virus control, cytokine production and cell-mediated cytotoxicity despite high expression of cytotoxic effector molecules. Single-cell RNA-sequencing (scRNA-seq) of NK cells along the time course of the entire COVID-19 disease spectrum reveals a unique gene expression signature. Transcriptional networks of interferon-driven NK cell activation are superimposed by a dominant TGFβ response signature with reduced expression of genes related to cell-cell adhesion, granule exocytosis and cell-mediated cytotoxicity. In severe COVID-19, serum levels of TGFβ peak during the first 2 weeks of infection, and serum obtained from these patients profoundly inhibits NK cell function in a TGFβ-dependent manner. Our data reveal that untimely production of TGFβ is a hallmark of severe COVID-19 and may inhibit NK cell function and early virus control.